



HAL
open science

Qualitative approach to better understand the trajectory of patients with early and moderate stage CKD

Agnès Oude Engberink, Gérard Bourrel, Olivier Moranne

► To cite this version:

Agnès Oude Engberink, Gérard Bourrel, Olivier Moranne. Qualitative approach to better understand the trajectory of patients with early and moderate stage CKD. *Clinical Kidney Journal*, 2022, 15 (11), pp.2157-2158. 10.1093/ckj/sfac106 . hal-03696670

HAL Id: hal-03696670

<https://hal.umontpellier.fr/hal-03696670>

Submitted on 7 Jun 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

LETTER TO THE EDITOR

Qualitative approach to better understand the trajectory of patients with early and moderate stage CKD

Agnes Oude Engberink^{1,2,3}, Gerard Bourrel^{1,2,3} and Olivier Moranne^{1,2,4} 

¹Département Universitaire de Médecine Générale, Université de Montpellier, Montpellier, France, ²Desbrest Institute of Epidemiology and Public Health, Université de Montpellier, Montpellier, France, ³Maison de Santé Pluriprofessionnelle Universitaire Avicenne, Cabestany, France and ⁴Service Néphrologie Dialyse Apherese, Hôpital Universitaire Caremeau, Nîmes, France

Correspondence to: Agnes Oude Engberink and Olivier Moranne; E-mail: agnes.oude-engberink@umontpellier.fr and olivier.moranne@chu-nimes.fr

The management of patients with chronic kidney disease (CKD) is complex. Although well-defined in the advanced stages, obstacles in terms of organization of care and therapeutic management persist [1]. The organization of the screening phase and the articulation between primary and secondary care actors is a matter of debate and needs to be better studied (why, when and how), especially as this is an issue for optimizing patient follow-up in all countries [2]. Guidelines for management, and in particular referral to nephrologists, are different and partially address the management of heterogeneous prognoses among at-risk populations [3]. Although the involvement of primary care providers in early-stage management seems essential to early diagnosis to preserve the nephron reserve, co-management with nephrologists remains complex in practice [4]. Recent studies show that in the field, referral of patients to nephrologists does not correspond to the recommendations [5] and the lack of secondary care providers will not allow the recommendations to be applied [6]. These difficulties encountered by primary care providers raise a number of questions that need to be explored and understood: What are their representations of early-stage renal disease? How do they make an aetiological and prognostic diagnosis? On what criteria do they refer patients to the nephrologists?

Despite recommendations for the publication of qualitative research studies, there are still solid obstacles in the medical community linked to negative representations and a lack of knowledge of these concepts and methods [7]. An Aus-

tralian study addressed the inadequacy of the evidence-based medicine (EBM) model as it is used by omitting the patient's perspective and professional expertise, whereas they were included in developing the EBM concept [8]. The research and clinical community, seeking to understand the gap between guidelines and real-world practice, would benefit from publishing more original qualitative studies to disseminate missing knowledge from the experience of all stakeholders. This would help primary care professionals to clarify their interventions at an early stage and optimize referral to the nephrologist.

Qualitative research studies human phenomena in their real contexts, interpreting them through specific scientific procedures of data collection (mainly semidirected, individual or group interviews) and analysis. Phenomenological approaches allow us to understand a phenomenon based on the experience of the actors and are sources of innovative data [9]. An example of a qualitative study has been applied to polycystic kidney disease, with an emphasis on the patient's perspective through the Standardised Outcomes in Nephrology project [10]. Various international qualitative studies have explored the perspectives of some of the stakeholders in the CKD care pathway specifically in primary care [11]. The difficulties encountered by general practitioners and registered practical nurses in announcing CKD are related to an uncertain progression to an advanced stage and the fear of worrying patients [12]. No study on early-stage CKD has integrated the experience of the different actors in the care pathway at all levels of care (patients

Received: 19.4.2022; Editorial decision: 22.4.2022

© The Author(s) 2022. Published by Oxford University Press on behalf of the ERA. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

and primary, secondary and tertiary care professionals), nor has it used the phenomenological semi-pragmatic approach in the analysis of the data. This method makes it possible to develop a collection device that facilitates the explanation of the lived experience and the reflexivity of the participant and to analyse them with a scientific procedure, limiting the researcher's interpretation bias. In this context, we need to plan some studies to explore and describe the management of patients with early to moderate stage CKD with the phenomenological qualitative experience of the actors (patients and health professionals), regardless of the level of recourse to care (primary, secondary and tertiary) in a large population and area.

CONFLICT OF INTEREST STATEMENT

None declared.

REFERENCES

- Raffray M, Bayat S, Campéon et al. The pre-dialysis care trajectory of chronic kidney disease patients and the start of dialysis in emergency: a mixed method study protocol. *Int J Environ Res Public Health* 2019; **16**: 5010
- Tonelli M, Dickinson JA. Early detection of CKD: implications for low-income, middle-income, and high-income countries. *J Am Soc Nephrol* 2020; **31**: 1931–1940
- Weckmann GFC, Stracke S, Haase A et al. Diagnosis and management of non-dialysis chronic kidney disease in ambulatory care: a systematic review of clinical practice guidelines. *BMC Nephrol* 2018; **19**: 258
- Greer RC, Liu Y, Cavanaugh K et al. Primary care physicians' perceived barriers to nephrology referral and co-management of patients with CKD: a qualitative study. *J Gen Intern Med* 2019; **34**: 1228–1235
- Schulz C., Messikh Z., Reboul P et al. Characteristics of outpatients referred for a first consultation with a nephrologist: impact of different guidelines. *J Nephrol* 2022; doi: 10.1007/s40620-021-01204-w
- Torreggiani M, Chatrenet A, Fois A et al. Unmet needs for CKD care: from the general population to the CKD clinics—how many patients are we missing? *Clin Kidney J* 2021; **14**: 2246–2254
- Taquette SR, Minayo MCdeS, Rodrigues AdeO. The perceptions of medical researchers on qualitative methodologies. *Cad Saude Publica* 2015; **31**: 722–732
- Fernandez A, Sturmberg J, Lukersmith S et al. Evidence-based medicine: is it a bridge too far? *Health Res Policy Syst* 2015; **13**: 66
- Emiliussen J, Engelsen S, Christiansen R et al. We are all in it!: Phenomenological qualitative research and embeddedness. *Int J Qual Methods* 2021; **20**: 1609406921995304
- Cho Y, Sautenet B, Rangan G et al. Standardised Outcomes in Nephrology—Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease. *Trials* 2017; **18**: 560
- Nihat A, Lusignan S de, Thomas N et al. What drives quality improvement in chronic kidney disease (CKD) in primary care: process evaluation of the Quality Improvement in Chronic Kidney Disease (QICKD) trial. *BMJ Open* 2016; **6**: e008480
- Blakeman T, Protheroe J, Chew-Graham C et al. Understanding the management of early-stage chronic kidney disease in primary care: a qualitative study. *Br J Gen Pract* 2012; **62**: e233–e242

NephroCan

Rethinking Hemodialysis

NephroCan is a Canadian, fully integrated product and service provider for patients affected by chronic kidney failure and needing hemodialysis (HD) therapy. Our company offers a broad range of HD products including machinery: hemodialysis machine, central and portable reverse osmosis (RO) systems, patient chairs, and disposables: dialyzers, bloodlines, fistula needles, and bicarbonate cartridges and bags.

NephroCan's dialyzers (NephroFilters) are made with high-quality materials and pass rigorous testing to ensure safety, effectiveness, and efficacy. We offer a variety of NephroFilters to assist nephrologists and other healthcare providers in administering personalized care for their patients. NephroFilters are low flux or high-flux permeability and adaptable to different hemodialysis machines, designed for ease of use by healthcare professionals.

Our HD machine (NephroHDM) features technology that enables precise and customized treatment for each patient. Our goal is to improve clinical outcomes and patient safety. The NephroHDM offers various therapeutic options that allow healthcare providers to tailor hemodialysis sessions based on each patient's specific needs. The machine is practical, with an intuitive interface for a fast, easy set up, and safe monitoring of HD treatments.

NephroCan's CE-certified products are trusted by healthcare professionals around the world. Our commitment to quality and safety is reflected in our operations and processes, which ensure our products provide patients with the best hemodialysis treatment throughout their ESRD journey.

Our distribution partners and end users agree on several reasons why NephroCan presents a unique offering:

1. Extensive product portfolio

NephroCan offers a wide range of products and services that cover the "A to Z" of the hemodialysis spectrum. This broad portfolio provides integrated solutions and comprehensive treatments for dialysis patients with various medical needs.

2. Commitment to innovation

NephroCan is committed to innovation and invests heavily in research and development to create new products that can improve patient outcomes. Our focus is to develop products and technologies that will better serve the healthcare industry in the coming years.

3. Global perspective

With an existing presence in the EU, Africa, Asia, and the Middle East, NephroCan's goal is to expand our reach and serve patients in diverse geographical areas. This global vision allows us to share best practices and leverage expertise across regions to improve patient care.

4. Patient and family-centred care approach

NephroCan places a strong emphasis on putting patients and their families first. We tailor our products and services to meet the uniqueness of the communities we serve. This philosophy is reflected in our commitment to quality and safety, ensuring NephroCan is a trusted provider of hemodialysis products.

You can learn more about how our products are driving positive change in the industry and improving patient outcomes worldwide by visiting our website: www.NephroCan.com.

We invite you to see our product portfolio in person at the upcoming ERA 2023 congress:



**June
15th - 17th**



**MiCo - Milano
Convention Center**



**Booth number
C.100**